Overview
AVIR market data
Price History
AVIR price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for AVIR. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
Atea Pharmaceuticals Initiates First-in-human Phase 1 Clinical Trial Of AT-587 For Hepatitis E Virus InfectionBenzinga · Jul 14, 2026, 11:05 AM
Atea Pharma Completes Patient Enrollment In C-FORWARD, Phase 3 Clinical Trial Outside North America, Evaluating Regimen Of Bemnifosbuvir And Ruzasvir For Treatment Of Hepatitis C Virus InfectionBenzinga · Jun 25, 2026, 11:15 AM
Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026Globenewswire Inc · May 27, 2026, 11:15 AM
Atea Pharmaceuticals' BEM/RZR Phase 1 Results Show Low Drug-Drug Interaction Risk With Commonly Used Medications For Hepatitis C PatientsBenzinga · May 27, 2026, 11:09 AM
Atea Pharmaceuticals Q1 2026 Earnings Call: Complete TranscriptBenzinga · May 12, 2026, 9:20 PM
8-K filing — Atea Pharmaceuticals, Inc. (AVIR)SEC EDGAR · May 12, 2026, 8:17 PM